Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
28 Mayo 2024 - 6:02AM
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies and vaccines, today
announced its expected upcoming inclusion in the Russell 3000®
Index, according to preliminary Russell reconstruction information
posted on the FTSE Russell website. The newly reconstructed index
will take effect after the market closes on June 28, 2024.
“Inclusion of Ocugen to the Russell 3000® Index is our latest
milestone, adding to what has already been a transformational year
for the Company with three of our game-changing modifier gene
therapies targeting blindness diseases—both rare and those
affecting millions—in clinical trials,” said Dr. Shankar Musunuri,
Chairman, CEO, and Co-founder of Ocugen. “This ranking signifies
the value of our pipeline, including the recently initiated Phase 3
liMeliGhT clinical trial of OCU400 for broad retinitis pigmentosa,
and robust growth strategy, supporting our efforts to enable
long-term shareholder value, garner significant visibility of
Ocugen within the investment community, and broaden our shareholder
base.”
The annual Russell 3000® Index reconstitution measures the
performance of the largest 3,000 U.S. companies representing
approximately 96% of the investable U.S. equity market as of
Tuesday, April 30.
Membership in the U.S. Russell 3000® remains in place for one
year and means automatic inclusion in the appropriate growth and
value style indexes. FTSE Russell determines membership for its
Russell indexes primarily by objective, market-capitalization
rankings, and style attributes.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Russell’s U.S. indexes serve as the
benchmark for about $10.5 trillion in assets as of the close of
December 2023. Russell indexes are part of FTSE Russell, a leading
global index provider.
About FTSE Russell: FTSE
Russell is a leading global provider of benchmarking, analytics,
and data solutions for investors, giving them a precise view of the
market relevant to their investment process. A comprehensive range
of reliable and accurate indexes provides investors worldwide with
the tools they require to measure and benchmark markets across
asset classes, styles, or strategies.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. For over 30 years,
leading asset owners, asset managers, ETF providers and investment
banks have chosen FTSE Russell indexes to benchmark their
investment performance and create ETFs, structured products, and
index-based derivatives.
FTSE Russell is focused on applying the highest industry
standards in index design and governance, employing transparent
rules-based methodology informed by independent committees of
leading market participants. FTSE Russell fully embraces the IOSCO
Principles, and its Statement of Compliance has received
independent assurance. Index innovation is driven by client needs
and customer partnerships, allowing FTSE Russell to continually
enhance the breadth, depth and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group. For
more information, visit: https://www.lseg.com/en/ftse-russell.
About Ocugen, Inc.Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies and vaccines that
improve health and offer hope for patients across the globe. We are
making an impact on patient’s lives through courageous
innovation—forging new scientific paths that harness our unique
intellectual and human capital. Our breakthrough modifier gene
therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more
at www.ocugen.com and follow us on X
and LinkedIn.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, including, but not limited to, statements
regarding the Company’s expected inclusion in the Russell 3000®
Index, qualitative assessments of available data, potential
benefits, expectations for ongoing clinical trials, anticipated
regulatory filings and anticipated development timelines, which are
subject to risks and uncertainties. We may, in some cases, use
terms such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” or other
words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Such statements are
subject to numerous important factors, risks, and uncertainties
that may cause actual events or results to differ materially from
our current expectations, including, but not limited to, the risks
that changes may be made to the preliminary Russell reconstruction
lists prior to finalization, that preliminary, interim and top-line
clinical trial results may not be indicative of, and may differ
from, final clinical data; that unfavorable new clinical trial data
may emerge in ongoing clinical trials or through further analyses
of existing clinical trial data; that earlier non-clinical and
clinical data and testing of may not be predictive of the results
or success of later clinical trials; and that that clinical trial
data are subject to differing interpretations and assessments,
including by regulatory authorities. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (SEC), including the risk
factors described in the section entitled “Risk Factors” in the
quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events, or otherwise, after the date of this
press release.
Contact:Tiffany HamiltonHead of
CommunicationsTiffany.Hamilton@ocugen.com
Ocugen (NASDAQ:OCGN)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Ocugen (NASDAQ:OCGN)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024